Bacterial Membrane Vesicles as a Novel Vaccine Platform against SARS-CoV-2
Open Access
- 20 August 2024
- journal article
- review article
- Published by Springer Nature in Current Microbiology
- Vol. 81 (10) , 1-13
Abstract
Throughout history, infectious diseases have plagued humanity, with outbreaks occurring regularly worldwide. Not every outbreak affects people globally; however, in the case of Coronavirus Disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), it reached a pandemic level within a remarkably short period. Fortunately, advancements in medicine and biotechnology have facilitated swift responses to the disease, resulting in the development of therapeutics and vaccines. Nevertheless, the persistent spread of the virus and the emergence of new variants underscore the necessity for protective interventions, leading researchers to seek more effective vaccines. Despite the presence of various types of vaccines, including mRNA and inactivated vaccines against SARS-CoV-2, new platforms have been investigated since the pandemic, and research on bacterial membrane vesicles (BMVs) has demonstrated their potential as a novel COVID-19 vaccine platform. Researchers have explored different strategies for BMV-based COVID-19 vaccines, such as mixing the vesicles with antigenic components of the virus due to their adjuvant capacity or decorating the vesicles with the viral antigens to create adjuvanted delivery systems. These approaches have presented promising results in inducing robust immune responses, but obstacles such as reproducibility in obtaining and homogeneous characterization of BMVs remain in developing vesicle-based vaccines. Overall, the development of BMV-based vaccines represents a novel and promising strategy in the fight against COVID-19. Additional research and clinical trials are needed to further evaluate the potential of these vaccines to offer long-lasting protection against SARS-CoV-2 and its evolving variants.Keywords
This publication has 80 references indexed in Scilit:
- Extracellular Vesicle‐Inspired Therapeutic Strategies for the COVID‐19Advanced Healthcare Materials, 2024
- Genetically Engineered Cellular Nanovesicles: Theories, Design and PerspectiveAdvanced Functional Materials, 2024
- Cell‐engineered virus‐mimetic nanovesicles for vaccination against enveloped virusesJournal of Extracellular Vesicles, 2024
- Bacterial Membrane Vesicles: Physiological Roles, Infection Immunology, and ApplicationsAdvanced Science, 2023
- Spike protein mediated membrane fusion during SARS‐CoV‐2 infectionJournal of Medical Virology, 2022
- SARS-CoV-2 cell entry beyond the ACE2 receptorMolecular Biology Reports, 2022
- A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variantsJournal of Extracellular Vesicles, 2022
- SARS‐CoV‐2 Omicron variant: Characteristics and preventionMedcomm, 2021
- Gram‐positive bacteria produce membrane vesicles: Proteomics‐based characterization of Staphylococcus aureus ‐derived membrane vesiclesProteomics, 2009
- Characterization of Escherichia coli expressing an Lpp’OmpA(46-159)-PhoA fusion protein localized in the outer membraneApplied Microbiology and Biotechnology, 1996